TNFRSF10B

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tumor necrosis factor receptor superfamily, member 10b

PDB rendering based on 1d0g.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols TNFRSF10B ; CD262; DR5; KILLER; KILLER/DR5; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; ZTNFR9
External IDs OMIM603612 HomoloGene117702 ChEMBL: 1075153 GeneCards: TNFRSF10B Gene
RNA expression pattern
PBB GE TNFRSF10B 209295 at tn.png
PBB GE TNFRSF10B 209294 x at tn.png
PBB GE TNFRSF10B 210405 x at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 8795 n/a
Ensembl ENSG00000120889 n/a
UniProt O14763 n/a
RefSeq (mRNA) NM_003842 n/a
RefSeq (protein) NP_003833 n/a
Location (UCSC) Chr 8:
22.88 – 22.93 Mb
n/a
PubMed search [1] n/a

Tumor necrosis factor receptor superfamily, member 10b, official symbol TNFRSF10B, is a human gene. Also known as: DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5

The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces apoptosis signal. Mice have a homologous gene, tnfrsf10b, that has been essential in the elucidation of the function of this gene in humans. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.[1]

Interactions[edit]

TNFRSF10B has been shown to interact with FADD,[2][3] TRAIL,[4][5][6] Caspase 10[2][7] and Caspase 8.[2][7]

Cancer Therapy[edit]

Monoclonal antibodies targeting Death Receptor 5 (TNFRSF10B) have been developed and are currently under clinical trials for patients suffer from a variety of cancer types, see Tigatuzumab (CS-1008).

See also[edit]


References[edit]

  1. ^ "Entrez Gene: TNFRSF10B tumor necrosis factor receptor superfamily, member 10b". 
  2. ^ a b c Gajate, Consuelo; Mollinedo Faustino (March 2005). "Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy". J. Biol. Chem. (United States) 280 (12): 11641–7. doi:10.1074/jbc.M411781200. ISSN 0021-9258. PMID 15659383. 
  3. ^ Chaudhary, P M; Eby M, Jasmin A, Bookwalter A, Murray J, Hood L (December 1997). "Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway". Immunity (UNITED STATES) 7 (6): 821–30. doi:10.1016/S1074-7613(00)80400-8. ISSN 1074-7613. PMID 9430227. 
  4. ^ Kaptein, A; Jansen M, Dilaver G, Kitson J, Dash L, Wang E, Owen M J, Bodmer J L, Tschopp J, Farrow S N (November 2000). "Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3)". FEBS Lett. (NETHERLANDS) 485 (2-3): 135–41. doi:10.1016/S0014-5793(00)02219-5. ISSN 0014-5793. PMID 11094155. 
  5. ^ Walczak, H; Degli-Esposti M A, Johnson R S, Smolak P J, Waugh J Y, Boiani N, Timour M S, Gerhart M J, Schooley K A, Smith C A, Goodwin R G, Rauch C T (September 1997). "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL". EMBO J. (ENGLAND) 16 (17): 5386–97. doi:10.1093/emboj/16.17.5386. ISSN 0261-4189. PMC 1170170. PMID 9311998. 
  6. ^ Hymowitz, S G; Christinger H W, Fuh G, Ultsch M, O'Connell M, Kelley R F, Ashkenazi A, de Vos A M (October 1999). "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5". Mol. Cell (UNITED STATES) 4 (4): 563–71. doi:10.1016/S1097-2765(00)80207-5. ISSN 1097-2765. PMID 10549288. 
  7. ^ a b MacFarlane, M; Ahmad M, Srinivasula S M, Fernandes-Alnemri T, Cohen G M, Alnemri E S (October 1997). "Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL". J. Biol. Chem. (UNITED STATES) 272 (41): 25417–20. doi:10.1074/jbc.272.41.25417. ISSN 0021-9258. PMID 9325248. 

Further reading[edit]

  • Abe K, Kurakin A, Mohseni-Maybodi M, et al. (2001). "The complexity of TNF-related apoptosis-inducing ligand.". Ann. N. Y. Acad. Sci. 926 (1): 52–63. doi:10.1111/j.1749-6632.2000.tb05598.x. PMID 11193041. 
  • Cha SS, Song YL, Oh BH (2004). "Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL:sDR5 complex.". Vitam. Horm. 67: 1–17. doi:10.1016/S0083-6729(04)67001-4. PMID 15110168. 
  • Kimberley FC, Screaton GR (2005). "Following a TRAIL: update on a ligand and its five receptors.". Cell Res. 14 (5): 359–72. doi:10.1038/sj.cr.7290236. PMID 15538968. 
  • Pan G, Ni J, Wei YF, et al. (1997). "An antagonist decoy receptor and a death domain-containing receptor for TRAIL.". Science 277 (5327): 815–8. doi:10.1126/science.277.5327.815. PMID 9242610. 
  • Sheridan JP, Marsters SA, Pitti RM, et al. (1997). "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.". Science 277 (5327): 818–21. doi:10.1126/science.277.5327.818. PMID 9242611. 
  • Screaton GR, Mongkolsapaya J, Xu XN, et al. (1998). "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL.". Curr. Biol. 7 (9): 693–6. doi:10.1016/S0960-9822(06)00297-1. PMID 9285725. 
  • Walczak H, Degli-Esposti MA, Johnson RS, et al. (1997). "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.". EMBO J. 16 (17): 5386–97. doi:10.1093/emboj/16.17.5386. PMC 1170170. PMID 9311998. 
  • MacFarlane M, Ahmad M, Srinivasula SM, et al. (1997). "Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL.". J. Biol. Chem. 272 (41): 25417–20. doi:10.1074/jbc.272.41.25417. PMID 9325248. 
  • Wu GS, Burns TF, McDonald ER, et al. (1997). "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene.". Nat. Genet. 17 (2): 141–3. doi:10.1038/ng1097-141. PMID 9326928. 
  • Schneider P, Bodmer JL, Thome M, et al. (1997). "Characterization of two receptors for TRAIL.". FEBS Lett. 416 (3): 329–34. doi:10.1016/S0014-5793(97)01231-3. PMID 9373179. 
  • Marsters SA, Sheridan JP, Pitti RM, et al. (1998). "A novel receptor for Apo2L/TRAIL contains a truncated death domain.". Curr. Biol. 7 (12): 1003–6. doi:10.1016/S0960-9822(06)00422-2. PMID 9382840. 
  • Chaudhary PM, Eby M, Jasmin A, et al. (1998). "Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway.". Immunity 7 (6): 821–30. doi:10.1016/S1074-7613(00)80400-8. PMID 9430227. 
  • Schneider P, Thome M, Burns K, et al. (1998). "TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.". Immunity 7 (6): 831–6. doi:10.1016/S1074-7613(00)80401-X. PMID 9430228. 
  • Pai SI, Wu GS, Ozören N, et al. (1998). "Rare loss-of-function mutation of a death receptor gene in head and neck cancer.". Cancer Res. 58 (16): 3513–8. PMID 9721851. 
  • Arai T, Akiyama Y, Okabe S, et al. (1999). "Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas.". Cancer Lett. 133 (2): 197–204. doi:10.1016/S0304-3835(98)00230-4. PMID 10072170. 
  • Mongkolsapaya J, Grimes JM, Chen N, et al. (2002). "Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.". Nat. Struct. Biol. 6 (11): 1048–53. doi:10.1038/14935. PMID 10542098. 
  • Hymowitz SG, Christinger HW, Fuh G, et al. (1999). "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.". Mol. Cell 4 (4): 563–71. doi:10.1016/S1097-2765(00)80207-5. PMID 10549288. 
  • Kuang AA, Diehl GE, Zhang J, Winoto A (2000). "FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts.". J. Biol. Chem. 275 (33): 25065–8. doi:10.1074/jbc.C000284200. PMID 10862756. 
  • Trauzold A, Wermann H, Arlt A, et al. (2001). "CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells.". Oncogene 20 (31): 4258–69. doi:10.1038/sj.onc.1204559. PMID 11464292. 

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.